Quartile | CRP (mg/L) | Kaplan-Meier estimate (n=450) | HR (95% CI)* | p value | |
Lenzilumab | Placebo | ||||
1 | <41 (n=113) | 54/56 (96) (86 to 99) | 47/57 (82) (69 to 90) | 8.20 (1.74 to 38.69) | 0.0079 |
2 | 41<79 (n=112) | 50/56 (89) (77 to 95) | 46/56 (82) (69 to 90) | 1.55 (0.58 to 4.15) | 0.3860 |
3 | 79<137 (n=112) | 40/47 (85) (71 to 92) | 48/65 (73) (60 to 82) | 2.25 (1.04 to 4.88) | 0.0407 |
4 | ≥137 (n=113) | 45/62 (72) (59 to 82) | 37/51 (72) (58 to 83) | 1.17 (0.58 to 2.35) | 0.6582 |
*Cox proportional hazard model for time to event with age (≤65,>65) and severity (severe, critical) strata as covariates.
†All data censored at 28 days following enrolment.
‡mITT, modified intention to treat population; all participants with baseline CRP values collected.
CRP, C reactive protein; SWOV, survival without invasive mechanical ventilation.